Camurus third quarter revenue beats expectations on Buvidal gains

Camurus’ third-quarter revenue exceeded estimates by 4%, while operating profit was 21% above analyst expectations, led by Buvidal; cash holdings rose to SEK4.4 billion from SEK4.1 billion in the prior quarter. The company maintained its 2026 revenue guidance of SEK2.6–2.9 billion and operating result guidance of SEK0.9–1.2 billion, saying it expects results in the upper half of both ranges. The SORENTO Phase III primary analysis is expected by year-end 2026, with topline data in Q1 2027; Oczyesa’s December 18 PDUFA date could be extended by about three months.

Analysis

The earnings quality is better than the headline beat alone suggests: Buvidal’s patient growth and modest margin/expense leverage support a repeatable operating trajectory, while the Brixadi royalty miss shows that not every product leg is tracking equally. The key question is whether Buvidal’s growth reflects durable treatment switching and access expansion or a finite catch-up in a few markets. Prison access is a meaningful UK channel catalyst, but also leaves some growth exposed to procurement and policy decisions. The read-through for Indivior and other opioid-use-disorder treatment providers is mixed: Buvidal may take share from daily and other long-acting options, but expanding treatment access could also grow the category rather than produce one-for-one displacement.

Near term, upper-half guidance language can support estimates, but the potential Oczyesa review extension adds timing uncertainty and makes its current uptake a weak basis for underwriting near-term earnings. The more consequential catalyst is SORENTO: topline data is not expected until Q1 2027, so this is a months-long clinical catalyst, not an immediate earnings driver. The Brixadi milestone is not a reason to extrapolate recurring royalties; verify the terms and recognition schedule before modeling it as cash or operating momentum. Contrarian risk: the operating-profit beat may encourage investors to capitalize a near-term expense benefit as structural margin expansion. Falsifiers include slowing Buvidal patient additions, a guidance reset, weaker gross-margin progression, or a further regulatory delay for Oczyesa.

Key Decisions for Investors

• For a 1–3 month horizon, favor a measured long CAMX on post-results weakness rather than chasing the beat; the thesis is Buvidal-led execution plus upper-half guidance, not a near-term Oczyesa launch. Set an alert for a material slowdown in quarterly Buvidal patient additions or a guidance reduction.
• Do not treat the Brixadi milestone as recurring earnings support. Before revising estimates, verify the milestone payment’s timing, accounting treatment, and whether the royalty shortfall persists in subsequent updates.
• Keep Oczyesa as a catalyst watch, not a core near-term earnings assumption. Reassess after the FDA decision and confirmation of the manufacturing-site review timeline; a longer delay or launch-readiness issue would weaken the product optionality case.
• For longer-term exposure, monitor SORENTO enrollment-event progress toward the expected analysis and Q1 2027 topline. The clinical outcome is a material binary catalyst; avoid sizing the position as though success is assured.